Recruitment

Recruitment Status
Completed
Estimated Enrollment
80

Inclusion Criteria

2nd line treatment for metastatic disease
Immunotherapy (for example ipilimumab and/or anti-PD-L1/PD-1 therapies)
Chemotherapy regimens containing DTIC, TMZ and/or cisplatin
...
2nd line treatment for metastatic disease
Immunotherapy (for example ipilimumab and/or anti-PD-L1/PD-1 therapies)
Chemotherapy regimens containing DTIC, TMZ and/or cisplatin
Patients that present with advanced or metastatic (stage III/IV) malignant melanoma of the skin.
Patients were FFPE and fresh frozen tissue is available (both mandatory).
Patients ≥ 18 years of age.
BRAF and/or MEK inhibitors
Patient must be able to give own signed informed consent.
1st line treatment for metastatic disease
Patients with prior adjuvant treatment are allowed.
Adjuvant treatment

Summary

Conditions
  • Advanced Melanoma
  • Metastatic Melanoma
Type
Observational
Design
  • Observational Model: Cohort
  • Time Perspective: Prospective

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criteria

2nd line treatment for metastatic disease
Immunotherapy (for example ipilimumab and/or anti-PD-L1/PD-1 therapies)
Chemotherapy regimens containing DTIC, TMZ and/or cisplatin
...
2nd line treatment for metastatic disease
Immunotherapy (for example ipilimumab and/or anti-PD-L1/PD-1 therapies)
Chemotherapy regimens containing DTIC, TMZ and/or cisplatin
Patients that present with advanced or metastatic (stage III/IV) malignant melanoma of the skin.
Patients were FFPE and fresh frozen tissue is available (both mandatory).
Patients ≥ 18 years of age.
BRAF and/or MEK inhibitors
Patient must be able to give own signed informed consent.
1st line treatment for metastatic disease
Patients with prior adjuvant treatment are allowed.
Adjuvant treatment

Locations

Waterford
Dublin
Galway
Dublin
Dublin
...
Waterford
Dublin
Galway
Dublin
Dublin
Cork

Tracking Information

NCT #
NCT02177110
Collaborators
Not Provided
Investigators
Not Provided